Biomarkers and Prediction of Tigecycline Induced Coagulation Dysfunction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-05-01

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is to screen out the biomarkers and establish the model to predict coagulation dysfunction induced tigecycline

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Proactive Diagnostic Value of Hemostatic Biomarkers in Disseminated Intravascular Coagulation

NCT05995093

Disseminated Intravascular Coagulation

UNKNOWN

Studies of Apolipoprotein Genotyping on the Drug Treatment of Hyperlipidemic Patients

NCT00451464

Hyperlipidemia

COMPLETED

Latent TGF-β-binding Proteins Affect the Fibrotic Process in Renal Impairment and Cardiac Dysfunction

NCT04998227

Acute Coronary Syndrome Acute Coronary Syndrome With Renal Dysfunction

RECRUITING

Clinical Application of MDCT in Coronary Artery Disease

NCT00155012

Coronary Arteriosclerosis

UNKNOWN

Significance of Serum Tenascin C in Patients With Acute Aortic Disease

NCT02816892

Aortic Dissection

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The critically ill patients treated with tigecycline in in tensive care unit will be recruited and divided into tigecycline-induced coagulation dysfunction group and non-coagulation dysfunction group. The multi-omics will be used to screen out biomarkers for early prediction of coagulation dysfunction caused by tigecycline. Afterwards, machine learning methods will be adopted to establish the the early prediction model of tigecycline-induced coagulation dysfunction.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Blood Coagulation Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

coagulation dysfunction group

The critically ill patients in intensive care unit showed coagulation dysfunction after treated with tigecycline.

No interventions assigned to this group

non-coagulation dysfunction group

The critically ill patients in intensive care unit showed normal coagulation function after treated with tigecycline.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Inpatients receiving tigecycline treatment in the Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
* Intravenous tigecycline ≥ 3 days
* Monitoring the plasma concentration of tigecycline